The 10-second takeaway
Comparing the upcoming quarter with the prior-year quarter, average analyst estimates predict Henry Schein's revenues will grow 3.7% and EPS will increase 8.9%.
The average estimate for revenue is $2.21 billion. On the bottom line, the average EPS estimate is $1.10.
Last quarter, Henry Schein notched revenue of $2.10 billion. GAAP reported sales were 7.8% higher than the prior-year quarter's $1.95 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.98. GAAP EPS of $0.89 for Q1 were 8.5% higher than the prior-year quarter's $0.82 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 29.1%, 10 basis points better than the prior-year quarter. Operating margin was 6.9%, 50 basis points better than the prior-year quarter. Net margin was 3.8%, 10 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $8.98 billion. The average EPS estimate is $4.37.
The stock has a two-star rating (out of five) at Motley Fool CAPS, with 93 members out of 103 rating the stock outperform, and 10 members rating it underperform. Among 35 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 31 give Henry Schein a green thumbs-up, and four give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Henry Schein is hold, with an average price target of $75.54.
If you're interested in health care stocks like Henry Schein, you might want to expand your horizons to find maximum returns. Follow the money and meet a prime candidate for major returns in our new report, "Discover the Next Rule-Breaking Multibagger." Get instant access to this free report.
- Add Henry Schein to My Watchlist.